31 research outputs found
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial (Nature Medicine, (2021), 27, 10, (1752-1760), 10.1038/s41591-021-01499-z)
No full textIn the version of this Article initially published, there was an error in the author affiliations. Specifically, affiliation 27, corresponding to author Carlo Selmi, has been corrected from “Humanitas Research Hospital, Milan, Italy” to read: “Department of Biomedical Sciences, Humanitas University, Milan, Italy & IRCCS Humanitas Research Hospital, Milan, Italy.” The change has been made to the online version of the Article
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial (Nature Medicine, (2021), 27, 10, (1752-1760), 10.1038/s41591-021-01499-z)
No full textIn the version of this Article initially published, there was an error in the author affiliations. Specifically, affiliation 27, corresponding to author Carlo Selmi, has been corrected from “Humanitas Research Hospital, Milan, Italy” to read: “Department of Biomedical Sciences, Humanitas University, Milan, Italy & IRCCS Humanitas Research Hospital, Milan, Italy.” The change has been made to the online version of the Article. © The Author(s) 2021
mCluster: A Software Framework for Portable Device-Based Volunteer Computing
No full textRecent market forecasts predict that the portablecomputing trend will vastly spread, as by 2020 there will bemore than 3 billion LTE device users worldwide. Motivatedby this fact, many companies and research institutes havealready launched research projects that utilize portable devices, voluntarily provided by users, to perform the requiredcomputations. Many such projects employ Berkeley's BOINCmiddleware, since it can support a large variety of stationaryand mobile devices. However, currently available BOINChigh-level APIs, either do not support portable devices orlack advanced processing capabilities (such as inter-node taskdependencies) and/or easiness of use. To resolve these issues, we propose the mCluster software framework for applicationexecution powered by the BOINC middleware on portable devices. mCluster adopts a task-based programming model thatrequires simple, pragma-based annotations of the applicationsoftware, in order to dynamically resolve task dependencies. To evaluate our framework, we have have mapped a scientificapplication from the neuroscience domain on an small-scalednetwork of portable devices. mCluster significantly reducesthe required programming effort and complexity to efficientlymap BOINC-powered applications with task dependencies onportable devices compared to previous approaches
Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
No full textRecent research on antiretroviral treatment (ART) for HIV suggests that integrase strand transfer inhibitors (INSTIs) cause faster weight gain compared to other drug classes. Here, we investigated changes in body mass index (BMI) and obesity prevalence after treatment initiation and corresponding differences between drug classes. Data were derived from a large collaborative cohort in Greece. Included individuals were adults who started ART, in or after 2010, while previously ART naïve and achieved virologic response within the first year of ART. Data were analysed using mixed fractional polynomial models. INSTI regimens led to the more pronounced BMI increases, followed by boosted PI and NNRTI based regimens. Individuals with normal initial BMI are expected to gain 6 kg with an INSTI regimen compared to 4 kg with a boosted PI and less than 3 kg with a NNRTI regimen after four years of treatment. Prevalence of obesity was 5.7% at ART initiation and 12.2%, 14.2% and 18.1% after four years of treatment with NNRTIs, PIs, and INSTIs, respectively. Dolutegravir or Raltegravir were associated with marginally faster BMI increase compared to Elvitegravir. INSTIs are associated with faster weight gain. INSTIs’ increased risk of treatment emergent obesity and, possibly, weight-related co-morbidities should be judged against their improved efficacy and tolerability but increased clinical attention is required
Specificity of understanding of the basic theological and philosophical terms in Severus of Antioch’s teaching
No full textThis article focuses on the specific understanding of basic theological and philosophical terms of Severus of Antioch’s teaching. The author analyses such concepts as: "essence" (οὐσία), "hypostasis" (ὑπόστασις), "person" (πρόσωπον), "nature" (φύσις) and "energy" (ἐνέργεια). The research on the above terms is a necessary introduction to further study of christology of the most outstanding of the representatives of "moderate monophysism". As a result of the conducted research, the differences in the Severus of Antioch and the Diphysites’ understanding of the above-mentioned concepts were revealed. Of particular note is the interpretation of the concept of "φύσις", which for the Antiochian Patriarch is synonymous with the terms "ὑπόστασις" and "πρόσωπον". It also seems specific to interpret the term "ἐνέργεια", which, according to Severus, is not an attribute of a being, but is only a manifestation of a specific hypostasis/nature/person.Niniejszy artykuł poświęcony jest specyfice rozumienia podstawowych terminów teologiczno-filozoficznych w nauczaniu Sewera z Antiochii. Autor analizuje w nim takie pojęcia jak: „istota” (οὐσία), „hipostaza” (ὑπόστασις), „osoba” (πρόσωπον), „natura” (φύσις) oraz „energia” (ἐνέργεια). Zbadanie powyższych terminów to niezbędny wstęp do kolejnych rozważań nad chrystologią najwybitniejszego z przedstawicieli „umiarkowanego monofizyzmu”. W efekcie przeprowadzonych badań ujawnione zostały różnice w rozumieniu wspomnianych pojęć przez Sewerem z Antiochii i dyfizytów. Na szczególną uwagę zasługuje interpretacja pojęcia „φύσις”, które dla Antiocheńskiego Patriarchy jest synonimem terminów „ὑπόστασις” oraz „πρόσωπον”. Specyficzne wydaje się być również interpretowanie terminu „ἐνέργεια”, która, według Sewera, nie jest atrybutem istoty, a jest jedynie przejawianiem się konkretnej hipostazy/natury/[email protected]ścijańska Akademia Teologiczna w Warszawie, Wydział Teologiczny, PolskaAthanasii Alexandrini, (1857). Epistola ad Afros episcopos [w:] Patrologia Cursus Completus. Series Graeca 26. red. and ed. Jacques Paul Migne. Paris.Basilius Caesariensis, (1857) Contra Eunomium IV, 286-287 [w:] Patrologia Cursus Completus. Series Graeca 29, red. and ed. Jacques Paul Migne. Paris.Sévère d’Antioche, (1964-1971). Adversus Apologiam Iuliani 21 [w:] La polémique antijulianiste. [w:] Corpus Scriptorum Christianorum Orientalium T. 2B. ed. and trans. R. Hespel. Louvain: Durbecq.Severus Antiochenus, (1973). Letter 6 to Maron the reader [w:] A collection of Letters [w:] Patrologia Orientalis 14,12, ed. and trans. E. W. Brooks. Paris: Firmin-Didot.Severus Antiochenus, (1981). Epistola 3 ad Johannem abbatem [w:] Doctrina Patrum de Incarnatione Verbi. ed. R. Phanourgakis and E. Chrysos. Munster: Aschendorf.Severus Antiochenus, (1938). Liber contra impium Grammaticum [w:] Corpus Scriptorum Christianorum Orientalium 111-112. red. ed. and trans. J. Lebon. Louvain: Dubecq.Severus Antiochenus, (1949). Orationes ad Nephalium, eiusdem ac Sergii Grammatici epistulae mutuae [w:] Corpus Scriptorum Christianorum Orientalium 119-120. ed. and trans. J. Lebon. Louvain: Durbecq.Severus Antiochenus, (1952). Liber contra impium Grammaticum [w:] Corpus Scriptorum Christianorum Orientalium 94. ed. and trans. J. Lebon. Louvain: Durbecq.Dawydienkov, O. B. (2007). Christologiczeskaja sistiema Siewira Antiochijskogo. Moskwa: Prawosławnyj Swiato-Tichonowskij gumanitarnyj uniwiersitiet.Hainthaler, T. (2002). Ephraem von Antiochien und sein Neuchalcedonismus [w:] Grillmeier, A. Jesus der Christus im Glauben der Kirche 2, 3: Die Kirchen von Jerusalem und Antiochien nach 451 bis 600. Freiburg s. 357-373.Lebon, J. (1975). Christologia Sirijskogo monofizitstwa. red. N. A. Zabołotskij, Leningrad: Izdatielstwo Leningradskaja Duchownaja Akadiemija.Loure, V. M. (2006). Istorija Wizantijskoj filozofii. Sankt-Pietierburg: Axioma.Meyendorff, I. (2000). Iisus Christos w wostocznom prawosławnom bogosłowii. Moskva: Izdatielstwo Prawosławnogo Swiato-Tichonowskogo Bogosłowskogo instituta.Samuel, V. C. (1974). The Understanding of the Christological Definitions of both (Oriental Orthodox and Roman Catholic) Traditions in the Light of Post-Chalcedonian Theology. Wien: Wirtschaftsuniversität Wien.Sellers, R. V. (1953). The Council of Chalcedon: A Historical and Doctrinal Survey. London: S.P.C.K.Szukin, T. A. (2009). Sewir Antiochijskij [w:] Antologija wostoczno-chritianskoj bogosłowskoj mysli T. 1, Moskwa i Sankt-Pietierburg: Izdatielstwo «Nikieja» RCHGA. s. 623-636.269910
The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort
No full textCombined Antiretroviral therapy (cART) has improved life-expectancy of people living with HIV (PLHIV) but as they age, prevalence of chronic non-AIDS related comorbidities may increase. We study the evolution of HIV-disease markers and comorbidities’ prevalence in PLHIV in Greece. Two cross-sectional analyses (2003 and 2013) on data from the AMACS cohort were performed. Comparisons were based on population average models and were repeated for subjects under follow-up at both 2003 and 2013. 2,403 PLHIV were identified in 2003 and 4,910 in 2013 (1,730 contributing for both cross-sections). Individuals in 2013 were on average older, diagnosed/treated for HIV for longer, more likely to be on cART, viro-logically suppressed, and with higher CD4 counts. Chronic kidney disease, dyslipidemia and hypertension prevalence increased over time. There was an increase in prescription of lipid-lowering treatment (3.5% in 2003 vs. 7.7% 2013, p<0.001). Among 220 and 879 individuals eligible for Framingham 10-year Event Risk calculation, the proportion of patients in the high-risk group (>20%) increased from 18.2% to 22.2% (p = 0.002). Increase in the prevalence of comorbidities was more pronounced in the subset of patients who were followed in both 2003 and 2013. The increased availability and uptake of cART led to significant improvements in the immuno-virological status of PLHIV in Greece, but they aged alongside an increase in prevalence of non-AIDS related comorbidities. These results highlight the need for appropriate monitoring, optimal cART selection and long-term management and prevention strategies for such comorbidities. © 2018 Pantazis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/μL on ART
No full textIntroduction Clinical disadvantages of initiating ART at low CD4 counts have been clearly demonstrated but whether any excess risk remains even after reaching relatively high/safe CD4 levels remains unclear. We explore whether individuals starting ART with <500 CD4 cells/μL who increased their CD4 count above this level, have, from this point onwards, similar risk of clinical progression to serious AIDS/non-AIDS events or death with individuals starting ART with ≥500 CD4 cells/μL. Methods Data were derived from a multicenter cohort (AMACS). Adults, starting PI, NNRTI or INSTI based ART, in or after 2000 were eligible, provided they started ART with ≥500 (“High CD4”) or started with CD4 <500 cells/μL but surpassed this threshold while on ART (“Low CD4”). Baseline was the date of ART initiation (“High CD4”) or of first reaching 500 CD4 cells/μL (“Low CD4”). Survival analysis, allowing for competing risks, was used to explore the risk of progression to study’s endpoints. Results The study included 694 persons in the “High CD4” and 3,306 in the “Low CD4” group. Median (IQR) follow-up was 66 (36, 106) months. In total, 257 events (40 AIDS related, 217 SNAEs) were observed. Rates of progression did not differ significantly between the two groups but the subgroup of those initiating ART with <200 CD4 cells/μL had significantly higher risk of progression after baseline, compared to those in the “High CD4” group. Conclusions Individuals starting ART with <200 cells/μL remain on increased risk even after reaching 500 CD4 cells/μL. These patients should be closely followed. Copyright: © 2023 Pantazis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
HIV cascade of care in Greece: Useful insights from additional stages
No full textBackground Aiming to eliminate HIV infection, UNAIDS has set a global “90-90-90” target by 2020. We sought to construct a 6-stages HIV Cascade of Care (CoC) in Greece, overall and by risk group, to assess risk-group and stage-specific progress in achieving the UNAIDS target. Patients and methods Combining data from the HIV/AIDS surveillance system and a population-based HIV cohort study, the CoC included: i) number of people living with HIV (PLHIV) by end of 2013; ii) proportion of PLHIV ever diagnosed; iii) proportion of diagnosed linked-to-care iv) proportion of linked-to-care ever initiating antiretroviral therapy (ART); v) proportion of treated who retained-in-care vi) proportion of those retained-in-care who were virally suppressed (200 copies/mL) at their last visit (01/07/2012-31/12/2013). Results In 2013, 14147 PLHIV were in Greece. Overall, proportions of each stage in the cascade were: 78.4% diagnosed; 86% linked-to-care; 78.5% initiated ART; 86.4% retained-in-care, and 87.1% virally suppressed. Totally, 42.6% of all PLHIV were virally suppressed. The percentage diagnosed was lower among heterosexual men and women (heterosexuals) than in MSM (men who have sex with men) or PWID (people who inject drugs). Most MSM were linked to care (97.2% of diagnosed) while a substantial proportion of PWID were not (80.8% of diagnosed). Once treated, PWID remained in care in similar proportions to MSM. Unlike PWID, a high proportion of the retained in care MSM and heterosexuals achieved viral suppression. Conclusions At the end of 2013, we identified gaps in the HIV CoC in Greece, which differed across risk groups. Targeted interventions are critical in optimizing early diagnosis and timely linkage. A 6-stage CoC, stratified by risk group, can inform strategic public health planning in improving HIV treatment outcomes. © 2018 Vourli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
